1.57 USD
↘ 0.06 (3.68%)AT CLOSE (11:59 AM EDT)
Geron Corp
GERNNASDAQ • USD
1.57
↘ 0.01 (0.32%)
POST MARKET (AS OF 07:45 PM EDT)
Post Market
AS OF 07:45 PM EDT
1.57
↘ 0.01 (0.32%)
Market: CLOSED
Geron Corp (GERN) trades at $1.56 per share. The stock presents a mixed profile: our models indicate a Strong Buy for technical indicators, while underlying fundamentals flash a Sell. Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 2/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. Valuation metrics place GERN at a fair price relative to peers.
Technical & fundamental data as of Aug 6, 2026.
Open?$1.60
High?$1.62
Low?$1.53
Prev. Close?$1.63
Volume?16.2M
Avg. Volume?12.0M
VWAP?$1.57
Rel. Volume?1.35x
Bid / Ask
Bid?$1.56 × 100
Ask?$1.57 × 6.4K
Spread?$0.01
Midpoint?$1.57
Valuation & Ratios
Market Cap?1.0B
Shares Out?641.5M
Float?625.8M
Float %?97.6%
P/E Ratio?N/A
P/B Ratio?4.78
EPS?-$0.11
Dividend?0.00%
Ex-Dividend?N/A
RelatedALKS
News
Profile
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
Themes
Address
919 EAST HILLSDALE BOULEVARD
FOSTER CITY, CA 94404
Phone: (650) 473-7700
FOSTER CITY, CA 94404
Phone: (650) 473-7700
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?▲ Bullish(+2/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?12
Z-Score?0
Momentum?20
Short Sent.?39
Piotroski F-Score?2/9Weak
Altman Z-Score?-1.95Distress
Confidence?67%Moderate
Short InterestHigh
Short % of Float?11.17%High
Short Interest?69.9M
Days to Cover?6.8
Free Float625.8M
Avg Daily Volume10.4M
Settlement Date2026-07-15
Financial Health
Current Ratio?6.92Strong
Quick Ratio?5.16Strong
Cash Ratio?0.89Adequate
Debt/Equity?1.14Moderate
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score67/100
P/E?N/A▾
P/B?4.78FAIR▾
Peers50
S&P38
P/S?5.11FAIR▾
Peers50
S&P28
P/FCF?N/A▾
EV/EBITDA?-35.4CHEAP▾
Peers100
S&P97
EV/Sales?6.03HIGH▾
Peers50
S&P28
Returns & Efficiency
ROE?-30.9%WEAK▾
Peers50
S&P6
ROA?-13.0%WEAK▾
Peers50
S&P3
Cash Flow & Enterprise
FCF?$-114762000
Enterprise Value?$1.2B
Fundamentals ratios updated end of day